Single Centre Experience in Patients with Primary Hyperparathyroidism: Sporadic, Lithium-associated and in Multiple Endocrine Neoplasia

Abstract

Purpose It is assumed that primary hyperparathyroidism (pHPT) in Multiple Endocrine Neoplasia (MEN) and lithium-associated pHPT (LIHPT) are associated with multiple gland disease (MGD), persistence and recurrence. The studies purpose was to determine frequencies, clinical presentation and outcome of sporadic pHPT (spHPT), LIHPT and pHPT in MEN. Additional main outcome measures were the rates of MGD and persistence/recurrence.

Methods Retrospective analysis of medical records of 682 patients with pHPT who had attended the University Hospital of Marburg between 01–01–2004 and 30–06–2013. All patients were sent a questionnaire asking about their history of lithium medication.

Results Out of 682 patients, 557 underwent primary surgery (532 spHPT, 5 LIHPT, 20 MEN), 38 redo-surgery (31 spHPT, 7 MEN), 55 were in follow-up due to previous surgery (16 spHPT, 1 LIHPT, 38 MEN) and 37 were not operated (33 spHPT, 1 LIHPT, 3 MEN). Primary surgeries were successful in 97.4%, revealed singular adenomas in 92.4%, double adenomas in 2.9% and MGD in 3.4% of the cases. Rates of MGD in MEN1 (82.35%) were significantly higher than in spHPT (3.8%), while there was no significant difference between LIHPT (20%) and spHPT. Rates of persistence/recurrence did not significantly differ due to type of surgery (bilateral/unilateral) or type of HPT (spHPT/LIHPT/MEN).

Conclusions History of lithium medication is rare among pHPT patients. While MGD is common in MEN1, rates of MGD, persistence or recurrence in LIHPT were not significantly higher than in spHPT.

Key words

hyperparathyroidism - lithium - multiple endocrine neoplasia, multiple gland disease - outcome

^* Current Address: Sabine Dillenberger, Department of Pediatrics, University Clinic of Münster, Albert-Schweitzer-Campus 1, 48149 Münster.

Publikationsverlauf

Eingereicht: 17. November 2018
Eingereicht: 17. Mai 2019

Angenommen: 05. Juni 2019

Artikel online veröffentlicht:
14. August 2019

• References

• 1 Zahrani AA, Levine MA. Primary hyperparathyroidism. Lancet 1997; 349: 1233-1238
• 2 Silverberg SJ, Bilezikian JP. Evaluation and management of primary hyperparathyroidism. J Clin Endocrinol Metab 1996; 81: 2036-2040
• 3 Dotzenrath C, Kaetsch AK, Pfingsten H. et al. Neuropsychiatric and cognitive changes after surgery for primary hyperparathyroidism. World J Surg 2006; 30: 680-685
• 4 Delorme S, Hoffner S. Diagnostik des Hyperparathyreoidismus. Radiologe 2003; 43: 275-283
• 5 Twigt BA, Scholten A, Valk GD. et al. Differences between sporadic and MEN related primary hyperparathyroidism: Clinical expression, preoperative workup, operative strategy and follow-up. Orphanet J Rare Dis 2013; 8: 50
• 6 Hannan FM, Nesbit MA, Christie PT. et al. Familial isolated primary hyperparathyroidism caused by mutations of the MEN1 gene. Nat Clin Pract Endocrinol Metab 2008; 4: 53-58
• 7 Ruda JM, Hollenbeak CS, Stack BC. A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngol Head Neck Surg 2005; 132: 359-372
• 8 Iacobone M, Carnaille B, Palazzo FF. et al. Hereditary hyperparathyroidism-A consensus report of the European Society of Endocrine Surgeons (ESES). Langenbecks Arch Surg 2015; 400: 867-886
• 9 Phay JE, Moley FM, Laimore TC. Multiple endocrine neoplasias. Semin Surg Oncol 2000; 18: 324-332
• 10 Fyrsten E, Norlen O, Hessman O. et al. Long-term surveillance of treated hyperparathyroidism for multiple endocrine neoplasia type 1: Recurrence or hypoparathyroidism?. World J Surg 2015; 40: 615-662
• 11 Garfinkel PE, Ezrin C, Stancer HC. Hypothyroidism and hyperparathyroidism associated with lithium. Lancet 1973; 2: 331-332
• 12 Meehan AD, Humble MB, Yazarloo P. et al. The prevalence of lithium-associated hyperparathyroidism in a large Swedish population attending psychiatric outpatient units. J Clin Psychopharmacol 2015; 35: 279-285
• 13 Gitlin M. Lithium side effects and toxicity: Prevalence and management strategies. Int J Bipolar Disord 2016; 4: 27
• 14 Szalat A, Mazeh H, Freund HR. Lithium-associated hyperparathyroidism: Report of four cases and review of the literature. Eur J Endocrinol 2009; 160: 317-323
• 15 Brown EM. Lithium induces abnormal calcium-regulated PTH release in dispersed bovine parathyroid cells. J Clin Endocrinol Metab 1981; 52: 1046-1048
• 16 Haden ST, Stoll AL, McCormick S. et al. Alterations in parathyroid dynamics in lithium-treated subjects. J Clin Endocrinol Metab 1997; 82: 2844-2848
• 17 Komatsu M, Shimizu H, Tsuruta T. et al. Effect of lithium on serum calcium level and parathyroid function in manic-depressive patients. Endocr J 1995; 42: 691-695
• 18 Mak TW, Shek CC, Chow CC. et al. Effects of lithium therapy on bone mineral metabolism: A two-year prospective longitudinal study. J Clin Endocrinol Metab 1998; 83: 3857-3859
• 19 Birnbaum J, Klandorf H, Giuliano A. et al. Lithium stimulates the release of human parathyroid hormone in vitro. J Clin Endocrinol Metab 1988; 66: 1187-1191
• 20 Hundley JC, Woodrum DT, Saunders BD. et al. Revisiting lithium-associated hyperparathyroidism in the era of intraoperative parathyroid hormone monitoring. Surgery 2005; 138: 1027-1031
• 21 Järhult J, Ander S, Asking B. et al. Long-term results of surgery for lithium-associated hyperparathyroidism. Br J Surg 2010; 97: 1680-1685
• 22 Skandarajah AR, Palazzo FF, Henry JF. Lithium-associated hyperparathyroidism: Surgical strategies in the era of minimally invasive parathyroidectomy. World J Surg 2011; 35: 2432-2439
• 23 Norlen O, Sidhu S, Sywak M. et al. Long-term outcome after parathyroidectomy for lithium-induced hyperparathyroidism. Br J Surg 2014; 101: 1252-1256
• 24 Meehan AD, Udumyan R, Kardell M. et al. Lithium-associated hypercalcemia: Pathophysiology, prevalence, management. World J Surg 2018; 42: 415-424
• 25 Awad SS, Miskulin J, Thompson N. Parathyroid adenomas vs. four-gland hyperplasia as the cause of primary hyperparathyroidism in patients with prolonged lithium therapy. World J Surg 2003; 27: 486-488
• 26 Carchman E, Ogilvie J, Holst J. et al. Appropriate surgical treatment of lithium-associated hyperparathyroidism. World J Surg 2008; 32: 2195-2199
• 27 Marti JL, Yang CS, Carling T. et al. Surgical approach and outcomes in patients with lithium-associated hyperparathyroidism. Ann Surg Oncol 2012; 19: 3465-3471
• 28 Livingstone C, Rampes H. Lithium: A review of its metabolic adverse effects. J Psychopharmacol 2006; 20: 347-355
• 29 Ballehaninna UK, Nguyen SM, Chamberlain RS. Lithium associated hyperparathyroidism: An evidence based surgical approach. Surgical. Science 2011; 2: 468-475
• 30 Kallner G, Petterson U. Renal, thyroid and parathyroid function during lithium treatment: Laboratory tests in 207 people treated for 1–30 years. Acta Psychiatr Scand 1995; 91: 48-51
• 31 Abdullah H, Bliss R, Guinea AI. et al. Pathology and outcome of surgical treatment for lithium-associated hyperparathyroidism. Br J Surg 1999; 86: 91-93
• 32 Sneider MS, Solorzano CC, Montano RE. et al. Sporadic primary hyperparathyroidism in young individuals: Different disease and treatment?. J Surg Res 2009; 155: 100-103
• 33 Irvin GL, Carneiro DM, Solorzano CC. Progress in the operative management of sporadic primary hyperparathyroidism over 34 years. Ann Surg 2004; 239: 704-711
• 34 Udelsman R. Six Hundred Fifty-Six Consecutive Explorations for Primary Hyperparathyroidism. Ann Surg 2002; 235: 665-672
• 35 Karakas E, Schneider R, Rothmund M. et al. Initial surgery for benign primary hyperparathyroidism: An analysis of 1 300 patients in a teaching hospital. World J Surg 2014; 38: 2011-2018
• 36 Thakker RV. Multiple endocrine neoplasia-syndromes of the twentieth century. J Clin Endocrinol Metab 1998; 83: 2617-2620